Immune cell attack: new hope for tough melanoma?

NCT ID NCT07288203

First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 30 times

Summary

This study tests a personalized cell therapy called lifileucel (TIL) for people with advanced melanoma that has not responded to standard treatments. About 100 adults with stage III or IV melanoma will receive their own immune cells that have been specially grown in a lab to fight the cancer. The goal is to see if this treatment can shrink tumors and control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centre Hospitalier de l'Universite de Montreal

    Montral, Quebec, Canada, H2X 0A9, Canada

  • Greenslopes Private Hospital

    Greenslopes, Queensland, 4120, Australia

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada, M5G 2M9, Canada

  • Royal Marsden Hospital

    London, SW3 6JJ, United Kingdom

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

Conditions

Explore the condition pages connected to this study.